| Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency (NCT04240054) | Medical College of Wisconsin | 2021-11-02 |
| Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma (NCT03492268) | Bioray Laboratories | 2021-11-01 |
| Isatuximab in Type I Cryoglobulinemia (NCT05114109) | Assistance Publique - Hôpitaux de Paris | 2021-11-01 |
| A Study of NINLARO® in Chinese Adults With Multiple Myeloma (NCT05013190) | Takeda | 2021-10-29 |
| A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab (NCT04302324) | Weill Medical College of Cornell University | 2021-10-28 |
| A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma (NCT05139225) | Memorial Sloan Kettering Cancer Center | 2021-10-28 |
| Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone (NCT05509374) | Samsung Medical Center | 2021-10-28 |
| MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (NCT05090566) | Pfizer | 2021-10-27 |
| Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell Transplant (NCT04985409) | Cedars-Sinai Medical Center | 2021-10-26 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma (NCT04234022) | The Royal Wolverhampton Hospitals NHS Trust | 2021-10-22 |
| Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients (NCT04634435) | Biohaven Pharmaceuticals, Inc. | 2021-10-21 |
| Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide (NCT06069024) | Qianfoshan Hospital | 2021-10-15 |
| A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (NCT05083169) | Janssen Research & Development, LLC | 2021-10-14 |
| A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (NCT05014412) | Pfizer | 2021-10-07 |
| Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT04975399) | Celgene | 2021-10-05 |
| TriPRIL CAR T Cells in Multiple Myeloma (NCT05020444) | Marcela V. Maus, M.D.,Ph.D. | 2021-10-05 |
| A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (NCT05020236) | Pfizer | 2021-10-04 |
| In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET (NCT05093335) | Memorial Sloan Kettering Cancer Center | 2021-10-01 |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers (NCT05024045) | Eli Lilly and Company | 2021-09-30 |
| Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) (NCT04991103) | University of Alabama at Birmingham | 2021-09-22 |
| A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (NCT05050097) | Janssen Research & Development, LLC | 2021-09-22 |
| Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma (NCT04561492) | Nantes University Hospital | 2021-09-21 |
| Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma (NCT05243212) | Sheba Medical Center | 2021-09-19 |
| Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma (NCT04782687) | US Oncology Research | 2021-09-10 |
| Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM (NCT06099912) | FengYan Jin | 2021-09-08 |
| Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies (NCT04702932) | Assistance Publique - Hôpitaux de Paris | 2021-09-01 |
| To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma (NCT04582539) | Incyte Corporation | 2021-08-19 |
| A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (NCT04923893) | Janssen Research & Development, LLC | 2021-08-19 |
| COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies (NCT05028374) | Barbara Ann Karmanos Cancer Institute | 2021-08-17 |
| 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma (NCT05364177) | Peking Union Medical College Hospital | 2021-08-11 |
| Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine (NCT03762291) | Baylor College of Medicine | 2021-08-06 |
| Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression (NCT04872023) | Rennes University Hospital | 2021-07-29 |
| Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM (NCT07217184) | GlaxoSmithKline | 2021-07-29 |
| China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (NCT06868654) | GlaxoSmithKline | 2021-07-28 |
| Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (NCT06868667) | GlaxoSmithKline | 2021-07-28 |
| Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma (NCT04635189) | University of Rochester | 2021-07-27 |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT04910568) | Genentech, Inc. | 2021-07-26 |
| Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide (NCT04989140) | Peking Union Medical College Hospital | 2021-07-26 |
| Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). (NCT04751877) | Poitiers University Hospital | 2021-07-17 |
| Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events (NCT05123001) | Stanford University | 2021-07-15 |
| Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM (NCT04653246) | Jacob Laubach, MD | 2021-07-13 |
| Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML (NCT04887259) | Lava Therapeutics | 2021-07-12 |
| Selinexor in Combination With Thalidomide and Dexamethasone in RRMM (NCT04891744) | Li Zheng | 2021-07-06 |
| Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma (NCT04230031) | Wake Forest University Health Sciences | 2021-07-02 |
| B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma (NCT05150522) | Shenzhen University General Hospital | 2021-07-01 |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH (NCT05283993) | Peking University First Hospital | 2021-07-01 |
| Feasibility Study of an ePRO Monitoring for Patients With Multiple Myeloma and Development of Item Lists (NCT05036863) | Medical University Innsbruck | 2021-07-01 |
| REST - Replacing Steroids in the Transplant Ineligble (NCT04939844) | Oslo University Hospital | 2021-06-29 |
| Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients (NCT04935580) | Shanghai Changzheng Hospital | 2021-06-28 |
| Impact of a Sensory Rehabilitation Program on Olfactory-gustatory Alterations in Patients Treated With Chemotherapy for Haematological Cancer (NCT04716153) | University Hospital, Montpellier | 2021-06-25 |
| Study of Dara-Pembro for Multiple Myeloma Patients (NCT04361851) | Wake Forest University Health Sciences | 2021-06-09 |
| A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma (NCT05016778) | Zhejiang University | 2021-06-08 |
| Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma (NCT04558931) | Karolinska Institutet | 2021-06-02 |
| Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (NCT04855136) | Celgene | 2021-06-01 |
| Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma (NCT05006469) | Liao Aijun | 2021-06-01 |
| Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse (NCT04656951) | University of Cologne | 2021-06-01 |
| A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma (NCT04918511) | Oncopeptides AB | 2021-05-27 |
| Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple Myeloma (NCT06170151) | IRCCS San Raffaele | 2021-05-24 |
| ATG-010(Selinexor) in Combination With Chemotherapy in RRMM (NCT04877275) | Chunyan Sun, MD | 2021-05-21 |
| Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma (NCT04521335) | University of Utah | 2021-05-21 |
| A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma (NCT04773522) | Janssen Pharmaceutical K.K. | 2021-05-20 |
| Personalized Autologous Transplant for Multiple Myeloma (NCT04483206) | Emory University | 2021-05-20 |
| Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma (NCT04822337) | Wake Forest University Health Sciences | 2021-05-19 |
| Double Filtration Plasmapheresis Combined With Chemotherapy (NCT04836871) | Fuling Zhou | 2021-05-15 |
| A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (NCT04688853) | Gadeta B.V. | 2021-05-13 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) (NCT04682405) | Washington University School of Medicine | 2021-05-05 |
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy (NCT04847050) | National Cancer Institute (NCI) | 2021-04-28 |
| Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma (NCT04756726) | C4 Therapeutics, Inc. | 2021-04-27 |
| Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma (NCT04818372) | Keymed Biosciences Co.Ltd | 2021-04-26 |
| A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (NCT04398680) | GlaxoSmithKline | 2021-04-20 |
| Biology and Genetics of Smouldering Myeloma (NCT05047107) | University College, London | 2021-04-15 |
| Covid-19 Vaccine Responsiveness in MM and Waldenstrom (NCT04830046) | Massachusetts General Hospital | 2021-04-15 |
| APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma (NCT04674514) | Ascentage Pharma Group Inc. | 2021-04-13 |
| Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (NCT04802356) | PETHEMA Foundation | 2021-04-07 |
| Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant (NCT04584307) | Natalie Callendar | 2021-04-01 |
| Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma. (NCT04533217) | Spine Centre of Southern Denmark | 2021-03-29 |
| A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM) (NCT04840680) | Takeda | 2021-03-22 |
| Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib (NCT04827563) | University of Chicago | 2021-03-22 |
| CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma (NCT04758767) | CASI pharmaceuticals, Inc. | 2021-03-22 |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (NCT04772989) | Arcus Biosciences, Inc. | 2021-03-19 |
| A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) (NCT05001087) | Fondazione EMN Italy Onlus | 2021-03-16 |
| A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (NCT04661137) | Hackensack Meridian Health | 2021-03-16 |
| Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT05346198) | Shanghai Simnova Biotechnology Co.,Ltd. | 2021-03-12 |
| A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (NCT04722146) | Janssen Research & Development, LLC | 2021-03-12 |
| The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma (NCT04760405) | University of Arizona | 2021-03-11 |
| A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma (NCT04814615) | Hoag Memorial Hospital Presbyterian | 2021-03-08 |
| DARA RVD For High Risk SMM (NCT04775550) | Omar Nadeem, MD | 2021-03-08 |
| a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease (NCT04776330) | Chongqing Precision Biotech Co., Ltd | 2021-03-07 |
| CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid-19) (NCT04659252) | Institute of Cancer Research, United Kingdom | 2021-03-04 |
| A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT04674813) | Juno Therapeutics, a Subsidiary of Celgene | 2021-02-24 |
| Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy (NCT04436029) | Cartesian Therapeutics | 2021-02-24 |
| Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NCT04808037) | Hellenic Society of Hematology | 2021-02-22 |
| Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients (NCT04564703) | Stichting European Myeloma Network | 2021-02-22 |
| Methods of T Cell Depletion Trial (MoTD) (NCT04888741) | University of Birmingham | 2021-02-22 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (NCT04629430) | University of Virginia | 2021-02-19 |
| A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE (NCT04258683) | Canadian Myeloma Research Group | 2021-02-17 |
| Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (NCT04392037) | Amsterdam UMC, location VUmc | 2021-02-17 |
| Patient Reported Outcomes and Patient Education in Cellular Therapy Patients (NCT04853277) | Dartmouth-Hitchcock Medical Center | 2021-02-07 |